high-risk

2:24
Better together? Ibrutinib and venetoclax for high-risk CLL
Nitin Jain
1:53
Nivolumab with ibrutinib for Richter’s transformation
Nitin Jain
2:33
Treatment options for high-risk myeloma
Annemiek Broyl
1:56
How do we define a ‘cure’ in myeloma?
Annemiek Broyl
2:48
MRD and disease eradication in myeloma
Jesús San Miguel
1:59
Smoldering multiple myeloma: what is the current definition & new screening programme
Irene Ghobrial
2:32
Improving the treatment landscape for DLBCL patients
Andrés Ferreri
2:14
How to define and treat high-risk lymphoma
Andrés Ferreri
1:58
Logistics for a technique to avoid GvHD
Denis C. Roy
1:56
Implications for a technique which eliminates GvHD
Denis C. Roy
2:08
Eradicating GvHD after haploidentical stem cell transplant
Denis C. Roy
1:05
When is the use of MRD appropriate?
Rafael Fonseca
1:06
Response to MM therapy can vary based on a variety of factors
Shaji Kumar
3:12
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trneny
3:17
Improving outcomes after transplant in AML
Charles Craddock
3:02
New technologies informing SOC in DLBCL
Christian Gisselbrecht
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals